Elai Davicioni
Inventor
Stats
- 5 US patents issued
- 33 US Applications filed
- most recent filing
This is official USPTO record data
Details
- 5 US Patents Issued
- 33 US Applications Filed
- 105 Total Citation Count
- Feb 20, 2024 Most Recent Filing
- May 28, 2009 Earliest Filing
Work History
| Patent Owner | Applications Filed | Year |
|---|---|---|
| MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 1
| 2013
|
| GENOMEDX BIOSCIENCES, INC. | 1
4 1 2 2 4 1 | 2009
2010 2012 2013 2014 2015 2016 |
| THE UNIVERSITY OF BRITISH COLUMBIA | 1
| 2014
|
| MADRYN HEALTH PARTNERS, LP | 4
1 4 | 2010
2013 2015 |
Inventor Addresses
| Address | Duration |
|---|---|
| La Jolla, CA, US | Mar 06, 14 - Dec 19, 24 |
| San Diego, CA, US | Jul 07, 22 - Sep 26, 24 |
| Vancouver, CA | Jun 09, 11 - Sep 24, 19 |
| West Vancouver, CA | May 10, 12 - May 10, 12 |
Technology Profile
| Technology | Matters | |
|---|---|---|
| C07H: | SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS | 2 |
| C12M: | APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY | 2 |
| C12N: | MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF | 2 |
Patents / Publication
| Patents / Publication # | Year of Publication / Issued | Title | Citations |
|---|---|---|---|
| 2024/0417,800 | 2024 | USE OF A GENETIC SIGNATURE DIAGNOSTICALLY TO EVALUATE TREATMENT STRATEGIES FOR PROSTATE CANCER | 0 |
| 2024/0360,517 | 2024 | SUBTYPING PROSTATE CANCER TO PREDICT RESPONSE TO HORMONE THERAPY | 0 |
| 2024/0319,192 | 2024 | USE OF IMMUNE CONTENT SCORES DIAGNOSTICALLY TO PREDICT RESPONSIVENESS OF PROSTATE CANCER PATIENTS TO IMMUNOTHERAPY | 0 |
| 11873532 | 2024 | Subtyping prostate cancer to predict response to hormone therapy | 0 |
| 2024/0002,944 | 2024 | METHODS AND GENOMIC CLASSIFIERS FOR IDENTIFYING HOMOLOGOUS RECOMBINATION DEFICIENCY PROSTATE CANCER | 0 |
We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level.
>
Upgrade to our Level for up to -1 portfolios!.